Kovai Medical (KOVAI)

FairStock Score: 43/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• High ROE of 24.22% and ROCE of 23.31% indicate strong capital efficiency
• Low debt/equity of 0.34 and Piotroski F-Score of 7/9 suggest a financially healthy balance sheet
• Consistent growth with sales up 14.63% and latest quarter revenue of ₹407 crore
• Latest quarterly net profit of ₹65 crore shows meaningful earnings power

Concerns

• Reported promoter holding of 0.00% is a major red flag or data anomaly that needs explanation
• Valuation is rich at P/E 24.53, P/B 6.41, and PEG 1.81 with a dividend yield of only 0.19%
• Profit growth of 12.49% trails sales growth of 14.63%, implying possible margin pressure
• FairStock Score of 42/100 is mixed, indicating the investment case is not compelling at this price

AI Analysis

Let me examine Kovai Medical not as a ticker but as a business. It earns a 24.22% return on equity and a 23.31% return on capital employed, with debt-equity of only 0.34. That tells me this hospital generates strong cash profits without leaning on borrowed money. The Piotroski F-score of 7 out of 9 reinforces a healthy financial position. But price matters. At ₹5,676.60, the market cap is ₹5,784 crore, or 24.53 times earnings and 6.41 times book value. For a company growing sales at 14.63% and profits at 12.49%, the PEG ratio works out to 1.81. That is not a margin of safety; it is a premium for quality. The dividend yield of 0.19% means I receive almost no cash while I wait. I am also troubled by the reported promoter holding of 0.00%. In my experience, owners who eat their own cooking are essential. A zero promoter stake, or a data quirk behind that number, demands an explanation before I put in a rupee. The latest quarter shows sales of ₹407 crore and net profit of ₹65 crore, respectable numbers, but profit growth is trailing sales growth, suggesting some margin pressure. The 52-week range of ₹5,010 to ₹6,279 tells me the market already has high expectations. A great business can still be a poor investment at the wrong price. This is a good, growing hospital business with excellent returns and low debt, but I am not being offered a bargain. The FairStock score of 42/100, 'mixed', matches my instinct. This is a quality compounder, but priced for perfection. I would wait for a lower price or clearer evidence that growth can accelerate without additional leverage.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer